NO995925L - Farmasoeytiske sammensetninger omfattende cyklodekstriner - Google Patents

Farmasoeytiske sammensetninger omfattende cyklodekstriner

Info

Publication number
NO995925L
NO995925L NO995925A NO995925A NO995925L NO 995925 L NO995925 L NO 995925L NO 995925 A NO995925 A NO 995925A NO 995925 A NO995925 A NO 995925A NO 995925 L NO995925 L NO 995925L
Authority
NO
Norway
Prior art keywords
cyclodextrins
pharmaceutical compositions
water
soluble
physiologically tolerable
Prior art date
Application number
NO995925A
Other languages
English (en)
Norwegian (no)
Other versions
NO995925D0 (no
Inventor
Roger Petrus Gerebe Vandecruys
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO995925D0 publication Critical patent/NO995925D0/no
Publication of NO995925L publication Critical patent/NO995925L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/738—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q3/00—Manicure or pedicure preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
NO995925A 1997-06-05 1999-12-03 Farmasoeytiske sammensetninger omfattende cyklodekstriner NO995925L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9711643.8A GB9711643D0 (en) 1997-06-05 1997-06-05 Glass thermoplastic systems
PCT/EP1998/003189 WO1998055148A1 (en) 1997-06-05 1998-05-27 Pharmaceutical compositions comprising cyclodextrins

Publications (2)

Publication Number Publication Date
NO995925D0 NO995925D0 (no) 1999-12-03
NO995925L true NO995925L (no) 2000-01-11

Family

ID=10813624

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995925A NO995925L (no) 1997-06-05 1999-12-03 Farmasoeytiske sammensetninger omfattende cyklodekstriner

Country Status (19)

Country Link
US (1) US20020150616A1 (de)
EP (1) EP0998304B1 (de)
JP (1) JP2002511073A (de)
KR (1) KR20010005852A (de)
CN (1) CN1258220A (de)
AR (1) AR012927A1 (de)
AT (1) ATE247489T1 (de)
AU (1) AU8108198A (de)
CA (1) CA2292506A1 (de)
DE (1) DE69817363T2 (de)
DK (1) DK0998304T3 (de)
ES (1) ES2206949T3 (de)
GB (1) GB9711643D0 (de)
HU (1) HUP0004924A2 (de)
IL (1) IL133293A0 (de)
NO (1) NO995925L (de)
PT (1) PT998304E (de)
WO (1) WO1998055148A1 (de)
ZA (1) ZA984849B (de)

Families Citing this family (396)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US7588793B1 (en) 1998-06-05 2009-09-15 Cadbury Adams Usa, Llc Enhanced flavoring compositions containing N-ethyl-p-menthane-3-carboxamide and method of making and using same
OA11740A (en) 1998-12-24 2005-05-13 Janssen Pharmaceutica Nv Controlled release galantamine composition.
EP1027885B1 (de) * 1999-02-09 2008-07-09 Pfizer Products Inc. Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
CN1156461C (zh) 1999-03-24 2004-07-07 R·P·希拉技术股份有限公司 改良的水溶性药物制剂
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
DE60004768T2 (de) * 1999-07-01 2004-07-08 Italfarmaco S.P.A. Komplexe von paroxetin mit cyclodextrin oder cyclodextrin derivaten
WO2001001955A1 (en) * 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6835717B2 (en) 2000-03-08 2004-12-28 The Johns Hopkins University School Of Medicine β-cyclodextrin compositions, and use to prevent transmission of sexually transmitted diseases
EP1278549B1 (de) 2000-05-02 2008-12-10 Theravance, Inc. Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
CZ299102B6 (cs) 2000-05-26 2008-04-23 Pfizer Inc. Tropanový derivát, zpusoby a meziprodukty pro jeho výrobu, léciva a lécivové kombinace s jeho obsahem
CN1322850C (zh) * 2000-06-02 2007-06-27 沈阳药科大学 盐酸尼卡地平粉针剂及其制备方法
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
CA2432319A1 (en) 2000-12-21 2002-07-18 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
AU2002242926B2 (en) 2001-04-10 2007-10-11 Pfizer Inc. Pyrazole derivatives for treating HIV
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
FR2827516B1 (fr) * 2001-07-19 2003-09-19 Servier Lab Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
CN101259289B (zh) * 2001-11-02 2012-05-30 嵌入治疗公司 用于rna干扰的治疗用途的方法及组合物
CA2363376A1 (en) * 2001-11-16 2003-05-16 Bernard Charles Sherman Solid pharmaceutical compositions for oral administration comprising itraconazole
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
OA12768A (en) 2002-02-11 2006-07-04 Pfizer Nicotinamide derivatives useful as PDE4 inhibitors.
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
AU2003257791A1 (en) * 2002-08-15 2004-03-29 Tong Liu Soild nano pharmaceutical formulation and preparation method thereof
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
RU2359698C2 (ru) * 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
US7445769B2 (en) 2002-10-31 2008-11-04 Cadbury Adams Usa Llc Compositions for removing stains from dental surfaces and methods of making and using the same
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
DE10260872B4 (de) 2002-12-23 2013-09-26 Beiersdorf Ag Verwendung von gelbildendem Polymer, Wasser, Alkohol und Meeresalgenextrakt zur Einstellung von Elastizität und Haftvermögen selbstklebender kosmetischer Polymermatrices
DE10260873A1 (de) 2002-12-23 2004-07-15 Beiersdorf Ag Selbstklebende Polymermatrix mit einem Gehalt an Meeresalgenextrakt und Glycerin
US7993654B2 (en) * 2002-12-23 2011-08-09 Beiersdorf Ag Self-adhesive polymer matrix containing sea algae extract
US20060177498A1 (en) * 2003-01-22 2006-08-10 Ramaswami Bharatrajan Solid pharmaceutical composition comprising ramipril
JP2006517981A (ja) * 2003-02-17 2006-08-03 サン・ファーマシューティカル・インダストリーズ・リミテッド 低用量コルチコステロイド組成物
EP1460064A1 (de) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide als beta-2 Agonisten
KR101129816B1 (ko) * 2003-03-28 2012-03-26 아레스 트레이딩 에스.아. 클라드리빈의 경구용 제형
KR20060011943A (ko) * 2003-03-28 2006-02-06 아이박스 코포레이션 향상된 경구 및 경점막 수송용 클라드리빈 제형
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
US7390518B2 (en) 2003-07-11 2008-06-24 Cadbury Adams Usa, Llc Stain removing chewing gum composition
DE10338544B4 (de) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccale Formulierungen des Galanthamins und deren Anwendungen
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
ATE539077T1 (de) 2003-09-03 2012-01-15 Pfizer Benzimidazolonverbindungen mit agonistischer wirkung am 5-ht4 rezeptor
ATE450535T1 (de) 2003-09-03 2009-12-15 Glaxo Group Ltd Neues verfahren zur herstellung von pleuromutilinderivaten
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
MXPA06002789A (es) 2003-09-12 2006-06-14 Pfizer Combinaciones que comprenden ligandos alfa-2-delta.
HRP20080052T3 (hr) 2003-10-03 2008-02-29 Pfizer Inc. Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US8389032B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition having selected particle size
US8591973B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for active components and a material having preselected hydrophobicity as part of an edible composition
US8591972B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Delivery system for coated active components as part of an edible composition
US9271904B2 (en) 2003-11-21 2016-03-01 Intercontinental Great Brands Llc Controlled release oral delivery systems
US20050112236A1 (en) 2003-11-21 2005-05-26 Navroz Boghani Delivery system for active components as part of an edible composition having preselected tensile strength
KR20060120208A (ko) 2003-11-21 2006-11-24 콤비네이토릭스, 인코포레이티드 염증성 질환의 치료 방법 및 시약
US8591968B2 (en) 2005-05-23 2013-11-26 Kraft Foods Global Brands Llc Edible composition including a delivery system for active components
US8597703B2 (en) 2005-05-23 2013-12-03 Kraft Foods Global Brands Llc Delivery system for active components as part of an edible composition including a ratio of encapsulating material and active component
US8389031B2 (en) 2005-05-23 2013-03-05 Kraft Foods Global Brands Llc Coated delivery system for active components as part of an edible composition
US8591974B2 (en) 2003-11-21 2013-11-26 Kraft Foods Global Brands Llc Delivery system for two or more active components as part of an edible composition
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1708718A1 (de) 2004-01-22 2006-10-11 Pfizer Limited Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität
AU2005214154B2 (en) 2004-01-22 2008-01-24 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
PT1708991E (pt) 2004-01-22 2007-12-14 Pfizer Derivados de sulfonamida para o tratamento de doenças
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
CA2560510C (en) 2004-03-18 2009-10-13 Pfizer Inc. N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides
AU2005225632B2 (en) 2004-03-23 2011-08-04 Pfizer Inc. Formamide derivatives useful as adrenoceptor
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
KR100479367B1 (ko) * 2004-04-13 2005-03-29 (주) 에프디엘 이트라코나졸을 포함하는 경구투여용 항진균제 조성물
AP2006003771A0 (en) 2004-04-30 2006-10-31 Warner Lambert Co Substituted morpholine compounds for the treatmentof central nervous system disorders
EP1742535A4 (de) * 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc Geschmacksverdeckte formulierungen mit sertralin und sulfoalkylethercyclodextrin
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (de) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
BRPI0512046A (pt) 2004-06-15 2008-02-06 Pfizer derivados de ácido benzimidazolona carboxìlico
US20050282895A1 (en) * 2004-06-21 2005-12-22 Dosch Michael H Antimicrobial compositions and methods of use thereof
US7641892B2 (en) 2004-07-29 2010-01-05 Cadburry Adams USA, LLC Tooth whitening compositions and delivery systems therefor
CA2576375C (en) * 2004-08-11 2010-12-21 Cadbury Adams Usa Llc Sensate compositions and delivery systems therefor
EP1778686B9 (de) 2004-08-12 2009-07-08 Pfizer Limited Triazolopyridinylsulfanylderivate als inhibitoren der p38-map-kinase
US20060068058A1 (en) * 2004-09-30 2006-03-30 Cadbury Adams Usa Llc Thermally stable, high tensile strength encapsulation compositions for actives
US7955630B2 (en) * 2004-09-30 2011-06-07 Kraft Foods Global Brands Llc Thermally stable, high tensile strength encapsulated actives
US7727565B2 (en) 2004-08-25 2010-06-01 Cadbury Adams Usa Llc Liquid-filled chewing gum composition
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
CN1325054C (zh) * 2004-09-29 2007-07-11 南京师范大学 盐酸哌唑嗪的环糊精包合物及其制备方法
ATE417830T1 (de) 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
GT200500317A (es) 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
JP4335120B2 (ja) 2004-11-08 2009-09-30 カゴメ株式会社 混合飲料の製造方法
US9198448B2 (en) * 2005-02-07 2015-12-01 Intercontinental Great Brands Llc Stable tooth whitening gum with reactive ingredients
CA2614223A1 (en) 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
AP2007004157A0 (en) 2005-03-17 2007-10-31 Pfizer N- (N-sulfonylaminomethyl) cyclo-propanecarboxamide derivatives useful for the treatment of pain
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
AU2006238747B2 (en) 2005-04-19 2012-04-26 King's College London Use
BRPI0609952A2 (pt) * 2005-04-24 2010-05-11 Wyeth Corp métodos para modular a função da bexiga
EP1888587A1 (de) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurinderivate als modulatoren des toll-like rezeptors zur behandlung von krebs und virusinfektionen wie hepatitis c
US7851006B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
US7851005B2 (en) 2005-05-23 2010-12-14 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
CA2604760C (en) 2005-05-23 2012-06-26 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
ES2277743B2 (es) * 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
CA2612287C (en) 2005-06-15 2011-01-25 Pfizer Limited Substituted arylpyrazoles for use against parasites
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20070221236A1 (en) * 2005-10-05 2007-09-27 Cadbury Adams Usa Llc. Cooling compositions including menthyl esters
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
CN101583620B (zh) 2005-11-28 2016-08-17 马里纳斯医药公司 加奈索酮组合物及其制备和使用方法
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
EP1973422B1 (de) * 2005-12-23 2014-06-11 Intercontinental Great Brands LLC Zusammensetzungen für die orale oder dermale abgabe, die ein wärmegefühl vermitteln
CN101346073B (zh) * 2005-12-23 2013-02-13 卡夫食品环球品牌有限责任公司 提供基本上类似于由薄荷醇提供的感觉的组合物
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
CA2647048A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
TW200806300A (en) * 2006-03-24 2008-02-01 Wyeth Corp New therapeutic combinations for the treatment of depression
PE20080125A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodo para modular la funcion de la vejiga
AU2007229491A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for treating cognitive and other disorders
PE20081192A1 (es) * 2006-03-24 2008-10-07 Wyeth Corp Tratamiento del dolor
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
GB2453475B (en) 2006-07-25 2011-01-19 Secr Defence Live vaccine strain
WO2008024914A2 (en) 2006-08-23 2008-02-28 Intellect Neurosciences Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
EP2068853A2 (de) 2006-09-15 2009-06-17 Stevia APS Behandlung von insulinresistenz oder erkrankungen im zusammenhang mit insulinresistenz mit bicyclo[3.2.1]octanen wie steviol und isosteviol
JP5140080B2 (ja) 2006-09-21 2013-02-06 ラクオリア創薬株式会社 選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
BRPI0719250A2 (pt) 2006-10-12 2015-06-16 Wyeth Corp Métodos e composições com opalescência reduzida.
SI2076508T1 (sl) 2006-10-18 2011-04-29 Pfizer Prod Inc Spojine biaril eter sečnine
EP2222631B1 (de) 2006-10-23 2011-08-17 Pfizer Inc. Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
EP2395077A1 (de) 2006-11-03 2011-12-14 Wyeth LLC Glycolysehemmstoffe in Zellkulturen
MX2009001711A (es) 2006-11-17 2009-05-08 Supernus Pharmaceuticals Inc Formulaciones de liberacion sostenida de topiramato.
AU2007325628A1 (en) * 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
EP2363113B1 (de) * 2006-12-04 2017-08-02 Supernus Pharmaceuticals, Inc. Topiramat-Formulierungen für verstärkte unmittelbare Freisetzung
JP4523073B2 (ja) 2007-02-06 2010-08-11 ファイザー・インク 癌を治療するためのＨＳＰ−９０阻害剤としての２−アミノ−５，７−ジヒドロ−６Ｈ−ピロロ［３，４−ｄ］ピリミジン誘導体
JP5586235B2 (ja) 2007-03-02 2014-09-10 ワイス・エルエルシー ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用
US20100216823A1 (en) * 2007-05-24 2010-08-26 Pfizer Inc. Spirocyclic Derivatives
EP2148692B1 (de) 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Mit hydantoin modifizierte melanocortin-rezeptorliganden
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
ES2452965T3 (es) 2007-09-05 2014-04-03 Rigel Pharmaceuticals, Inc. Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
CA2706368A1 (en) * 2007-11-20 2009-05-28 Cadbury Adams Usa Llc Dual coated confectionery product
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US20090275622A1 (en) * 2008-04-30 2009-11-05 Prasoona Linga Nizatidine formulations
JP5600104B2 (ja) 2008-08-01 2014-10-01 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド Ｔｏｌｌ様受容体アゴニスト処方物およびその使用
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
EP2163253B1 (de) 2008-09-15 2013-07-17 ULLRICH, Oliver Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
BRPI0921097B8 (pt) 2008-11-21 2021-05-25 Raqualia Pharma Inc composto ou seu sal farmaceuticamente aceitável, intermediário do composto, composição farmacêutica e uso do composto
KR101128450B1 (ko) * 2008-12-11 2012-03-28 (주)바이오제닉스 안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
WO2010080528A1 (en) 2008-12-17 2010-07-15 Genentech, Inc. Hepatitis c virus combination therapy
EA020460B1 (ru) 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
ES2520165T3 (es) 2009-01-14 2014-11-11 Novacta Biosystems Limited Derivados de desoxiactagardina
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
CN102388060B (zh) 2009-02-04 2014-09-10 诺瓦克塔生物系统有限公司 阿肽加定衍生物
EP2406281B1 (de) 2009-03-12 2016-02-17 Haase Investments UG Varianten des knochenmorphogenetischen proteins 2 (bone morphogenetic protein 2, bmp2) mit reduzierter bmp-antagonistischer empfindlichkeit
EP2233502A1 (de) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US20100291201A1 (en) * 2009-05-14 2010-11-18 Cerovene, Inc. Coated pharmaceutical capsule dosage form
SG175738A1 (en) 2009-05-29 2011-12-29 Pfizer Ltd Novel glucocorticoid receptor agonists
EP2266563A1 (de) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
RU2580320C2 (ru) 2009-08-18 2016-04-10 Вентиркс Фармасьютикалз, Инк. Замещенные бензоазепины в качестве модуляторов toll-подобного рецептора
JP5756804B2 (ja) 2009-08-18 2015-07-29 ベンティアールエックス ファーマシューティカルズ， インコーポレイテッドＶｅｎｔｉＲｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｔｏｌｌ様レセプターモジュレーターとしての置換ベンゾアゼピン
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
AU2010333804B2 (en) 2009-12-23 2015-07-16 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
EP2531519A1 (de) 2010-02-02 2012-12-12 Novacta Biosystems Limited Lantibiotische salze
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
CA2789606A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues as opioid receptor agonists
EP2566858A2 (de) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclische derivate als alk-hemmer
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
US9096558B2 (en) 2010-07-09 2015-08-04 Pfizer Limited N-sulfonylbenzamide compounds
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
ES2525581T3 (es) 2010-07-12 2014-12-26 Pfizer Limited Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
WO2012007868A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
EP2609105B1 (de) 2010-08-24 2016-03-09 Imperial Innovations Limited Glycodendrimere aus polypropyletheriminen
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
WO2012148548A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
CN102139115B (zh) * 2011-03-30 2012-12-05 天津红日药业股份有限公司 阿托伐他汀的环糊精包合物及其口服固体制剂的制备方法
PE20141050A1 (es) 2011-04-05 2014-08-30 Pfizer Ltd Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
MX350024B (es) 2011-05-18 2017-08-23 Raqualia Pharma Inc Formas polimorfas del ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2- benzisoxazol-3-il]oxi}metil)piperidin-1-il]metil}-tetrahidro-2h-p iran-4-carboxílico.
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
ES2564366T3 (es) 2011-07-13 2016-03-22 Pfizer Limited Análogos de encefalina
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2739274A1 (de) 2011-08-02 2014-06-11 Pensieve Biosciences Cyprus Limited Behandlung von kognitiver störung
WO2013017989A1 (en) 2011-08-02 2013-02-07 Pfizer Inc. Crizotinib for use in the treatment of cancer
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
UA109220C2 (uk) 2011-10-26 2015-07-27 Пфайзер Лімітед Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
JP6158817B2 (ja) 2011-10-28 2017-07-05 インヒビタクシン リミテッド 治療に有用なピリダジン誘導体
WO2013088315A1 (en) 2011-12-15 2013-06-20 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CA2860553C (en) 2012-01-04 2016-08-23 Pfizer Limited N-aminosulfonyl benzamides
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
TW201336527A (zh) * 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
LT2822953T (lt) 2012-03-06 2017-04-10 Pfizer Inc. Makrocikliniai dariniai, skirti proliferacinių ligų gydymui
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
CN104470500A (zh) * 2012-07-12 2015-03-25 赛诺菲 包含1-(6-{[6-(4-氟苯基)[1,2,4]三唑并[4,3-b]哒嗪-3-基]硫基}-1,3-苯并噻唑-2-基)-3-(2-吗啉-4-基乙基)尿素化合物的抗肿瘤组合物
IN2014KN02981A (de) * 2012-07-17 2015-05-08 Glaxosmithkline Llc
WO2014039831A1 (en) 2012-09-07 2014-03-13 Takeda Pharmaceutical Company Limited SUBSTITUTED-1,4-DIHYDROPYRAZOLO[4,3-b]INDOLES
EP2897950A1 (de) 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl-)amino-pyrimidin-5-carboxamide als milz-tyrosinkinasehemmer
CA2884848C (en) 2012-09-28 2017-08-22 Pfizer Inc. Benzamide and heterobenzamide compounds
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
EP2903986A1 (de) 2012-10-04 2015-08-12 Pfizer Limited Tropomyosin-assoziierte kinaseinhibitoren
JP5823657B1 (ja) 2012-11-08 2015-11-25 ファイザー・インク ドーパミンｄ１リガンドとしての複素芳香族化合物
SG11201502763VA (en) 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
HK1208457A1 (en) 2012-11-21 2016-03-04 拉夸里亚创药株式会社 Polymorph forms
MY176727A (en) 2012-12-03 2020-08-20 Pfizer Selective androgen receptor modulators
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
PL2958916T3 (pl) 2013-02-21 2019-01-31 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
EP2792360A1 (de) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
JP6026024B2 (ja) 2013-06-27 2016-11-16 ファイザー・インク 複素芳香族化合物およびそのドーパミンｄ１リガンドとしての使用
HK1223825A1 (zh) 2013-07-08 2017-08-11 Abbvie Inc. 包含阿曲生坦的稳定化药物剂型
PL3021832T3 (pl) * 2013-07-19 2021-08-23 Boehringer Ingelheim Vetmedica Gmbh Konserwowana ciekła wodna kompozycja farmaceutyczna zawierająca eteryfikowane pochodne cyklodekstryny
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
BR122019024673B1 (pt) 2013-12-04 2023-04-11 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
EP3083602A1 (de) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidin-ether-tropomyosin-vermittelte kinasehemmer
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
AR099052A1 (es) 2014-01-09 2016-06-29 Takeda Pharmaceuticals Co Derivados de azaindol
WO2015157509A1 (en) * 2014-04-10 2015-10-15 The Trustees Of The University Of Pennsylvania Compositions and methods for treating opioid receptor associated diseases
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
WO2015162516A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CR20160493A (es) 2014-04-25 2016-12-16 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
EP3134405B1 (de) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
CA2946990A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
EP3140298A1 (de) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-assoziierte kinaseinhibitoren
EP3143021B1 (de) 2014-05-14 2019-06-12 Pfizer Inc Pyrazolopyridine und pyrazolopyrimidine
CN106459025B (zh) 2014-05-15 2019-05-28 辉瑞公司 6-[(4r)-4-甲基-1，1-二氧化-1，2，6-噻二嗪烷-2-基]异喹啉-1-腈的结晶形式
CN107074837B (zh) 2014-05-20 2020-07-28 拉夸里亚创药株式会社 苯并异恶唑衍生物盐
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
CA2950393A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
JP6621477B2 (ja) 2014-12-18 2019-12-18 ファイザー・インク ピリミジンおよびトリアジン誘導体ならびにａｘｌ阻害薬としてのそれらの使用
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
PT3247371T (pt) 2015-01-22 2020-07-02 Phytoplant Res S L Métodos de purificação de canabinóides, composições e kits associados
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
CU20170105A7 (es) 2015-02-24 2017-10-05 Pfizer Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
WO2016148674A1 (en) 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases
UA121775C2 (uk) 2015-07-31 2020-07-27 Пфайзер Інк. 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl
US20180193335A1 (en) * 2015-10-12 2018-07-12 Vikash J. BHAGWANDIN Compositions, formulations, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors
EP3386983A1 (de) 2015-12-10 2018-10-17 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazin-derivate der formel (i) als gaba-rezeptormodulatoren zur verwendung bei der behandlung von epilepsie und schmerzen
ES2877089T3 (es) 2015-12-24 2021-11-16 Takeda Pharmaceuticals Co Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal
EP3399968B8 (de) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selektive inhibitoren von klinisch wichtigen mutanten der egfr-tyrosin-kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
ES2837018T3 (es) 2016-01-15 2021-06-29 Pfizer Ligandos del receptor D3 de dopamina de 6,7,8,9-tetrahidro-5H-pirido[2,3-d]azepina
DK3411047T3 (da) 2016-02-04 2021-06-28 Czap Res And Development Llc Kontrolleret udløsning og stratificeret cyclodextrin inklusionskompleks bæremedier
CN108884445A (zh) 2016-03-09 2018-11-23 北京智康博药肿瘤医学研究有限公司 肿瘤细胞悬浮培养物和相关方法
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
MX2019001153A (es) 2016-07-29 2019-06-10 Pfizer Peptidos ciclicos como antagonistas del receptor c5a.
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
JP6563623B1 (ja) 2016-08-15 2019-08-21 ファイザー・インク ピリドピリミジノンｃｄｋ２／４／６阻害剤
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP3558950B1 (de) 2016-12-20 2023-05-10 Oligomerix, Inc. Neuartige chinazolinone zur hemmung der bildung von tau-oligomeren und deren verfahren zur verwendung
EP3562483B1 (de) 2016-12-20 2025-09-03 Oligomerix, Inc. Neuartige benzofuran-, benzothiophen- und indolanaloga zur hemmung der bildung von tau-oligomeren und deren verwendung
KR20190104405A (ko) 2017-01-20 2019-09-09 화이자 인코포레이티드 Magl 억제제로서의 1,1,1-트리플루오로-3-히드록시프로판-2-일 카르바메이트 유도체
MX2019008690A (es) 2017-01-23 2019-09-18 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
US11426397B2 (en) 2017-03-26 2022-08-30 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
WO2019002889A1 (en) * 2017-06-30 2019-01-03 Industrial Technology Research Institute METHOD FOR TREATING AUTOIMMUNE NEUROLOGICAL DISEASE AND / OR NEURODEGENERATIVE DISEASE AND PHARMACEUTICAL FORMULAS FOR LIQUID GALENIC FORM AND CONTROLLED RELEASE GALENIC FORM
WO2019043634A2 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
TW202517628A (zh) 2017-09-11 2025-05-01 美商克魯松藥物公司 Shp2之八氫環戊烷并[c]吡咯別構抑制劑
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
EP3746419A1 (de) 2018-01-29 2020-12-09 Phytoplant Research S.L. Verfahren zur reinigung von cannabinoiden unter verwendung von flüssig-flüssigchromatografie
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
TWI741268B (zh) 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
WO2019180072A1 (en) 2018-03-22 2019-09-26 Bayer Pharma Aktiengesellschaft Parenteral pharmaceutical composition comprising neladenoson bialanate
CR20200503A (es) 2018-04-26 2020-12-17 Pfizer Inhibidores de cinasa dependientes de ciclina
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
US20210309669A1 (en) 2018-07-19 2021-10-07 Pfizer Inc. Heterocyclic Spiro Compounds As MAGL Inhibitors
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
MX2021006095A (es) 2018-11-29 2021-07-06 Pfizer Pirazoles como moduladores de hemoglobina.
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
TWI732431B (zh) 2019-01-23 2021-07-01 美商輝瑞股份有限公司 多形體
JP7094456B2 (ja) 2019-01-31 2022-07-01 ファイザー・インク Ｃｄｋ２阻害剤
TW202102498A (zh) 2019-03-22 2021-01-16 日商武田藥品工業股份有限公司 作為ripk2 抑制劑之吡啶稠合咪唑及吡咯衍生物
US12247015B2 (en) 2019-04-29 2025-03-11 Solent Therapeutics, Llc 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
KR20220044753A (ko) 2019-07-25 2022-04-11 큐라데브 파마 프라이버트 리미티드 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
PE20221341A1 (es) 2019-09-16 2022-09-13 Takeda Pharmaceuticals Co Derivados de piridazin-3(2h)-ona fusionados con azol
MX2022003633A (es) 2019-09-25 2022-04-19 Pfizer Moduladores poliheterociclicos de sting (estimulador de genes de interferon).
CN110538094B (zh) * 2019-09-27 2022-01-18 华南理工大学 一种均相亲水和多维稳定的紫檀芪@环糊精包合物及其制备方法
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
CN110898015A (zh) * 2019-12-31 2020-03-24 上海汉维生物医药科技有限公司 一种伊曲康唑制剂的制备方法
KR20220141328A (ko) 2020-02-12 2022-10-19 큐라데브 파마 프라이버트 리미티드 소분자 sting 길항제
EP4117635A1 (de) * 2020-03-10 2023-01-18 SeraNovo Holding B.V. Plattform mit fester, tief eutektischer lösungsmittelformulierung
NL2025092B1 (en) * 2020-03-10 2021-10-19 Seranovo Holding B V Solid deep eutectic solvent formulation platform
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
EP4121417A4 (de) * 2020-05-01 2023-08-09 University Of Southern California Antimikrobielle therapie auf cyclodextrinbasis
IL297838A (en) 2020-05-01 2023-01-01 Pfizer Azalactam compounds as hpk1 inhibitors
MY210588A (en) 2020-05-04 2025-10-01 Takeda Pharmaceuticals Co Luminally-acting n-(piperidin-4-yl)benzamide derivatives
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
KR102829078B1 (ko) 2020-06-30 2025-07-04 리유니온 뉴로사이언스 인코포레이티드 트립타민 전구약물
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
US20230242539A1 (en) 2020-07-15 2023-08-03 Pfizer Inc. Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
WO2022077034A1 (en) 2020-10-09 2022-04-14 Napa Therapeutics Ltd. Heteroaryl amide inhibitors of cd38
US12533326B2 (en) * 2021-02-22 2026-01-27 Salamat Pajoohan Parsian Pharmed Preparation of soluble form of curcumin
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
CN113081989B (zh) * 2021-03-29 2022-10-21 海南普利制药股份有限公司 别嘌醇缓释片剂
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
WO2022207673A1 (en) 2021-03-31 2022-10-06 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
JP2024516359A (ja) 2021-04-07 2024-04-15 ライフアーク Ｕｌｋ１／２阻害剤およびその使用
IL309252A (en) 2021-06-26 2024-02-01 Array Biopharma Inc Inhibitors of HER2 mutations
TW202321231A (zh) 2021-08-11 2023-06-01 印度商裘拉德製藥私人有限公司 作為sting拮抗劑之小分子尿素衍生物
TW202321232A (zh) 2021-08-11 2023-06-01 印度商裘拉德製藥私人有限公司 小分子sting拮抗劑
DK4441052T3 (da) 2021-12-01 2026-02-23 Fundacion Del Sector Publico Estatal Centro Nac De Investigaciones Oncologicas Carlos Iii F S P Cnio Forbindelser
EP4499224A1 (de) 2022-03-30 2025-02-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl oder piperidin-4-yl)acetamid-derivate
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
IL318404A (en) 2022-07-29 2025-03-01 Pfizer NOVEL ACC INHIBITORS
TW202417456A (zh) 2022-08-10 2024-05-01 日商武田藥品工業股份有限公司 雜環化合物
CN115487080A (zh) * 2022-09-23 2022-12-20 山东博科医用材料有限公司 补骨脂酚微胶囊及其制备方法
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
TW202428252A (zh) 2022-11-15 2024-07-16 英商克拉德夫製藥有限公司 類Cdc激酶之雜環抑制劑
JP2026503702A (ja) 2023-01-26 2026-01-29 武田薬品工業株式会社 神経変性疾患の処置に有用な１－アミノ－４－フェニルフタラジン誘導体
CN121127471A (zh) 2023-04-14 2025-12-12 武田药品工业株式会社 作为nlrp3抑制剂的吡唑并嘧啶衍生物
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
WO2025037213A1 (en) * 2023-08-11 2025-02-20 Mankind Pharma Ltd. Pharmaceutical formulations of gpr119 agonists and uses thereof
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025137437A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Solid forms of a gabaa receptor modulator and methods of its use
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025231370A1 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited Inhibitors of cd38
WO2025229624A2 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited New cd38 inhibitors
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033430B2 (ja) * 1980-05-12 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
FR2647015B1 (fr) * 1989-05-17 1994-05-06 Cird Gel aqueux a base d'acide retinoique et son utilisation en medecine humaine et en cosmetique
US5206025A (en) * 1989-05-24 1993-04-27 Rhone-Poulenc Sante Porous pharmaceutical form and its preparation
TW200402B (de) * 1990-08-13 1993-02-21 Senju Pharma Co
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
WO1994012217A1 (en) * 1992-12-02 1994-06-09 Insite Vision Incorporated Cyclodextrin and polymer based drug delivery system
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
SE501482C2 (sv) * 1993-06-24 1995-02-27 Leiras Oy Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
EP0689844A1 (de) * 1994-06-23 1996-01-03 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Mit Zyklodextrin gebildete Vinpocetinkomplexe, Zubereitungsverfahren und pharmazeutische Präparate, die sie enthalten
AU7637296A (en) * 1995-11-14 1997-06-05 Farmarc Nederland Bv Complex of naproxen and beta-cyclodextrin

Also Published As

Publication number Publication date
KR20010005852A (ko) 2001-01-15
DE69817363T2 (de) 2004-06-24
PT998304E (pt) 2004-01-30
IL133293A0 (en) 2001-04-30
CA2292506A1 (en) 1998-12-10
CN1258220A (zh) 2000-06-28
GB9711643D0 (en) 1997-07-30
EP0998304B1 (de) 2003-08-20
WO1998055148A1 (en) 1998-12-10
ES2206949T3 (es) 2004-05-16
AU8108198A (en) 1998-12-21
AR012927A1 (es) 2000-11-22
DE69817363D1 (de) 2003-09-25
HUP0004924A2 (hu) 2001-08-28
EP0998304A1 (de) 2000-05-10
JP2002511073A (ja) 2002-04-09
DK0998304T3 (da) 2003-12-01
ATE247489T1 (de) 2003-09-15
US20020150616A1 (en) 2002-10-17
NO995925D0 (no) 1999-12-03
ZA984849B (en) 1999-12-06

Similar Documents

Publication Publication Date Title
NO995925L (no) Farmasoeytiske sammensetninger omfattende cyklodekstriner
ATE428729T1 (de) Kovalent verbrückte insulindimere
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
GEP20063917B (en) Pulmonary administration of chemically modified insulin
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
NO20035264D0 (no) Preparater av lipidpolymerkonjugater
DE60205749D1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
ATE513541T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung von calcitonin
AU7207098A (en) Stabilization of acid sensitive benzimidazols with amino acid/cyclodextrin combinations
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
AR025937A1 (es) Composicion farmaceutica que comprende un antigeno, un inmunoestimulante y un adyuvante policationico.
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
BRPI0407583A (pt) solução oftálmica lìmpida e estável
HRP20030050B1 (en) Sustained-release preparations of quinolone antibiotics and method for preparation thereof
CY1106633T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιεχουν χαλκο, σαλικυλικο οξυ και βιταμινη c
YU8701A (sh) Nova oralna kompozicija
AU5376500A (en) Functional poly-alpha-aminoacid derivatives useful for the modification of biologically active materials and their application
WO2003082926A3 (en) Antimicrobial polymer conjugates
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
DE60111503D1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
AU2002217062A1 (en) Dental compounds with reduced temperature sensitivity
NO20021573D0 (no) Tverrbundne kopolymerer basert på ikke-tverrbundne polykarboksylkopolymerer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application